MedTrace Logo

Study of Ruxolitinib Cream in Adolescents With Atopic Dermatitis

NCT05456529 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 103

Last updated 2025-06-25

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the long-term safety and tolerability of ruxolitinib cream in adolescents with Atopic Dermatitis (AD).

Conditions

  • Atopic Dermatitis (AD)

Interventions

DRUG

Ruxolitinib Cream

Ruxolitinib cream 1.5% twice daily (BID) during the continuous and LTS treatment period.

Sponsors & Collaborators

Principal Investigators

  • Brett Angel, MD · Incyte Corporation

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
12 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-01
Primary Completion
2024-05-17
Completion
2024-05-17
FDA Drug
Yes

Countries

  • United States
  • Canada
  • Poland

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05456529 on ClinicalTrials.gov